Skip to main content
Erschienen in: Calcified Tissue International 2/2009

01.02.2009

The PHEX Transgene Corrects Mineralization Defects in 9-Month-Old Hypophosphatemic Mice

verfasst von: Adele Boskey, Aaron Frank, Yukiji Fujimoto, Lyudmila Spevak, Kostas Verdelis, Bruce Ellis, Nancy Troiano, William Philbrick, Thomas Carpenter

Erschienen in: Calcified Tissue International | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Hypophosphatemia is an X-linked dominant disorder resulting from a mutation in the PHEX gene. While osteoblast-specific expression of the PHEX transgene has been reported to decrease the phosphate wasting associated with the disease in male hypophosphatemic (HYP) mice, there are reports that the mineralization defect is only partially corrected in young animals. To test the hypothesis that osteoblast-specific expression of the PHEX gene for a longer time would correct the mineralization defect, this study examined the bones of 9-month-old male and female HYP mice and their wild-type controls with or without expression of the transgene under a collagen type I promoter. Serum phosphate levels, alkaline phosphatase activity, and FGF23 levels were also measured. Mineral analyses based on wide-angle X-ray diffraction, Fourier transform-infrared (FT-IR) spectroscopy, and FT-IR imaging confirmed the decreased mineral content and increased mineral crystal size in male HYP humerii compared to wild-type males and females with or without the transgene and in female HYP mice with or without the transgene. There was a significant increase in mineral content and a decrease in crystallinity in the HYP males’ bones with the transgene, compared to those without. Of interest, expression of the transgene in wild-type animals significantly increased the mineral content in both males and females without having a detectable effect on crystallinity or carbonate content. In contrast to the bones, based on micro-computed tomography and FT-IR imaging, at 9 months there were no significant differences between the HYP and the WT teeth, precluding analysis of the effect of the transgene.
Literatur
1.
Zurück zum Zitat Baum M, Syal A, Quigley R, Seikaly M (2006) Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia. Pediatr Nephrol 21:1067–1074PubMedCrossRef Baum M, Syal A, Quigley R, Seikaly M (2006) Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia. Pediatr Nephrol 21:1067–1074PubMedCrossRef
2.
Zurück zum Zitat Holm IA, Huang X, Kunkel LM (1997) Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797PubMed Holm IA, Huang X, Kunkel LM (1997) Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797PubMed
3.
Zurück zum Zitat Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS (1997) Pex/PEX Tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99:1200–1209PubMedCrossRef Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS (1997) Pex/PEX Tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99:1200–1209PubMedCrossRef
4.
Zurück zum Zitat Glorieux FH, Holick MF, Scriver CR, DeLuca HF (1973) X-linked hypophosphataemic rickets: inadequate therapeutic response to 1, 25-dihydroxycholecalciferol. Lancet 2:287–289PubMedCrossRef Glorieux FH, Holick MF, Scriver CR, DeLuca HF (1973) X-linked hypophosphataemic rickets: inadequate therapeutic response to 1, 25-dihydroxycholecalciferol. Lancet 2:287–289PubMedCrossRef
5.
Zurück zum Zitat Eicher EM, Southard JL, Scriver C, Glorieux FH (1976) Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci USA 73:4667–4671PubMedCrossRef Eicher EM, Southard JL, Scriver C, Glorieux FH (1976) Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci USA 73:4667–4671PubMedCrossRef
6.
Zurück zum Zitat Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher MA, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanauer A, Lehrach H, Goulding JN, O’Riordan JL (1997) Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 6:539–549PubMedCrossRef Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A, Macher MA, Questiaux E, Popowska E, Pronicka E, Read AP, Mokrzycki A, Glorieux FH, Drezner MK, Hanauer A, Lehrach H, Goulding JN, O’Riordan JL (1997) Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet 6:539–549PubMedCrossRef
7.
Zurück zum Zitat Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B (1996) cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36:22–28PubMedCrossRef Du L, Desbarats M, Viel J, Glorieux FH, Cawthorn C, Ecarot B (1996) cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36:22–28PubMedCrossRef
8.
Zurück zum Zitat Guo R, Quarles LD (1997) Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. J Bone Miner Res 12:1009–1017PubMedCrossRef Guo R, Quarles LD (1997) Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. J Bone Miner Res 12:1009–1017PubMedCrossRef
9.
Zurück zum Zitat Boskey AL, Gilder H, Neufeld E, Ecarot B, Glorieux FH (1991) Phospholipid changes in the bones of the hypophosphatemic mouse. Bone 12:345–351PubMedCrossRef Boskey AL, Gilder H, Neufeld E, Ecarot B, Glorieux FH (1991) Phospholipid changes in the bones of the hypophosphatemic mouse. Bone 12:345–351PubMedCrossRef
10.
Zurück zum Zitat Abe K, Ooshima T, Masatomi Y, Sobue S, Moriwaki Y (1989) Microscopic and crystallographic examinations of the teeth of the X-linked hypophosphatemic mouse. J Dent Res 68:1519–1524PubMed Abe K, Ooshima T, Masatomi Y, Sobue S, Moriwaki Y (1989) Microscopic and crystallographic examinations of the teeth of the X-linked hypophosphatemic mouse. J Dent Res 68:1519–1524PubMed
11.
Zurück zum Zitat Abe K, Ooshima T, Sobue S, Moriwaki Y (1989) The crystallinity of human deciduous teeth in hypophosphataemic vitamin D-resistant rickets. Arch Oral Biol 34:365–372PubMedCrossRef Abe K, Ooshima T, Sobue S, Moriwaki Y (1989) The crystallinity of human deciduous teeth in hypophosphataemic vitamin D-resistant rickets. Arch Oral Biol 34:365–372PubMedCrossRef
12.
Zurück zum Zitat Erben RG, Mayer D, Weber K, Jonsson K, Juppner H, Lanske B (2005) Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res 20:1149–1160PubMedCrossRef Erben RG, Mayer D, Weber K, Jonsson K, Juppner H, Lanske B (2005) Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res 20:1149–1160PubMedCrossRef
13.
Zurück zum Zitat Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, Karaplis AC (2002) Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 16:2913–2925PubMedCrossRef Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, Karaplis AC (2002) Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 16:2913–2925PubMedCrossRef
14.
Zurück zum Zitat Liu S, Guo R, Tu Q, Quarles LD (2002) Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 277:3686–3697PubMedCrossRef Liu S, Guo R, Tu Q, Quarles LD (2002) Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 277:3686–3697PubMedCrossRef
15.
Zurück zum Zitat Brault BA, Meyer MH, Meyer RA Jr, Iorio RJ (1987) Mineral uptake by the femora of older female X-linked hypophosphatemic (HYP) mice but not older male HYP mice. Clin Orthop Relat Res 222:289–299PubMed Brault BA, Meyer MH, Meyer RA Jr, Iorio RJ (1987) Mineral uptake by the femora of older female X-linked hypophosphatemic (HYP) mice but not older male HYP mice. Clin Orthop Relat Res 222:289–299PubMed
16.
Zurück zum Zitat Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP (2005) Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 20:1659–1668PubMedCrossRef Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP (2005) Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 20:1659–1668PubMedCrossRef
17.
Zurück zum Zitat Boskey AL, Young MF, Kilts T, Verdelis K (2005) Variation in mineral properties in normal and mutant bones and teeth. Cells Tissues Organs 181:144–153PubMedCrossRef Boskey AL, Young MF, Kilts T, Verdelis K (2005) Variation in mineral properties in normal and mutant bones and teeth. Cells Tissues Organs 181:144–153PubMedCrossRef
18.
Zurück zum Zitat Pavlin D, Lichtler AC, Bedalov A, Kream BE, Harrison JR, Thomas HF, Gronowicz GA, Clark SH, Woody CO, Rowe DW (1992) Differential utilization of regulatory domains within the alpha 1(I) collagen promoter in osseous and fibroblastic cells. J Cell Biol 116:227–236PubMedCrossRef Pavlin D, Lichtler AC, Bedalov A, Kream BE, Harrison JR, Thomas HF, Gronowicz GA, Clark SH, Woody CO, Rowe DW (1992) Differential utilization of regulatory domains within the alpha 1(I) collagen promoter in osseous and fibroblastic cells. J Cell Biol 116:227–236PubMedCrossRef
19.
Zurück zum Zitat Wysolmerski JJ, Broadus AE, Zhou J, Fuchs E, Milstone LM, Philbrick WM (1994) Overexpression of parathyroid hormone-related protein in the skin of transgenic mice interferes with hair follicle development. Proc Natl Acad Sci USA 91:1133–1137PubMedCrossRef Wysolmerski JJ, Broadus AE, Zhou J, Fuchs E, Milstone LM, Philbrick WM (1994) Overexpression of parathyroid hormone-related protein in the skin of transgenic mice interferes with hair follicle development. Proc Natl Acad Sci USA 91:1133–1137PubMedCrossRef
20.
Zurück zum Zitat Kacena MA, Troiano NW, Wilson KM, Coady CE, Horowitz MC (2004) Evaluation of two different methylmethacrylate processing, infiltration, and embedding techniques on the histological, histochemical, and immunohistochemical analysis of murine bone specimens. J Histotechnol 27:119–130 Kacena MA, Troiano NW, Wilson KM, Coady CE, Horowitz MC (2004) Evaluation of two different methylmethacrylate processing, infiltration, and embedding techniques on the histological, histochemical, and immunohistochemical analysis of murine bone specimens. J Histotechnol 27:119–130
21.
Zurück zum Zitat Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595–610PubMedCrossRef Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595–610PubMedCrossRef
22.
Zurück zum Zitat Boskey AL, Mendelsohn R (2005) Infrared spectroscopic characterization of mineralized tissues. Vib Spectrosc 38:107–114PubMedCrossRef Boskey AL, Mendelsohn R (2005) Infrared spectroscopic characterization of mineralized tissues. Vib Spectrosc 38:107–114PubMedCrossRef
23.
Zurück zum Zitat Yu X, White KE (2005) FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 16:221–232PubMedCrossRef Yu X, White KE (2005) FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 16:221–232PubMedCrossRef
24.
Zurück zum Zitat Camacho NP, Rimnac CM, Meyer RA Jr, Doty S, Boskey AL (1995) Effect of abnormal mineralization on the mechanical behavior of X-linked hypophosphatemic mice femora. Bone 17:271–278PubMedCrossRef Camacho NP, Rimnac CM, Meyer RA Jr, Doty S, Boskey AL (1995) Effect of abnormal mineralization on the mechanical behavior of X-linked hypophosphatemic mice femora. Bone 17:271–278PubMedCrossRef
25.
Zurück zum Zitat Soener S, RA, Meyer MH, Meyer RA Jr (1988) Ovariectomy abolishes the normalization of femoral mineral content in 40-week-old female X-linked hypophosphatemic mice. Miner Electrolyte Metab 14:321–331 Soener S, RA, Meyer MH, Meyer RA Jr (1988) Ovariectomy abolishes the normalization of femoral mineral content in 40-week-old female X-linked hypophosphatemic mice. Miner Electrolyte Metab 14:321–331
26.
Zurück zum Zitat Onishi T, Umemura S, Shintani S, Ooshima T (2008) Phex mutation causes overexpression of FGF23 in teeth. Arch Oral Biol. 53:99–104PubMedCrossRef Onishi T, Umemura S, Shintani S, Ooshima T (2008) Phex mutation causes overexpression of FGF23 in teeth. Arch Oral Biol. 53:99–104PubMedCrossRef
27.
Zurück zum Zitat Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE (2005) Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36:33–46PubMedCrossRef Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE (2005) Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36:33–46PubMedCrossRef
28.
Zurück zum Zitat Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR (2004) MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303–319PubMedCrossRef Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR (2004) MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303–319PubMedCrossRef
29.
Zurück zum Zitat Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS (2008) Degradation of MEPE, DMP1 and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757–1772PubMedCrossRef Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS (2008) Degradation of MEPE, DMP1 and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757–1772PubMedCrossRef
30.
Zurück zum Zitat Qin C, D’Souza R, Feng JQ (2007) Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res 86:1134–1141PubMedCrossRef Qin C, D’Souza R, Feng JQ (2007) Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res 86:1134–1141PubMedCrossRef
31.
Zurück zum Zitat Addison WN, Nakano Y, Loisel T, Crine P, McKee MD (2008) MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638–1649PubMedCrossRef Addison WN, Nakano Y, Loisel T, Crine P, McKee MD (2008) MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638–1649PubMedCrossRef
32.
Zurück zum Zitat Boskey AL (2007) Mineralization of bones and teeth. Elements 3:387–393CrossRef Boskey AL (2007) Mineralization of bones and teeth. Elements 3:387–393CrossRef
33.
Zurück zum Zitat Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD (2007) Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293:E1636–E1644PubMedCrossRef Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD (2007) Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293:E1636–E1644PubMedCrossRef
Metadaten
Titel
The PHEX Transgene Corrects Mineralization Defects in 9-Month-Old Hypophosphatemic Mice
verfasst von
Adele Boskey
Aaron Frank
Yukiji Fujimoto
Lyudmila Spevak
Kostas Verdelis
Bruce Ellis
Nancy Troiano
William Philbrick
Thomas Carpenter
Publikationsdatum
01.02.2009
Verlag
Springer-Verlag
Erschienen in
Calcified Tissue International / Ausgabe 2/2009
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-008-9201-y

Weitere Artikel der Ausgabe 2/2009

Calcified Tissue International 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.